Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial

被引：0

作者：

Graham McIlroy

Siân Lax

Charlotte Gaskell

Aimee Jackson

Malcolm Rhodes

Tania Seale

Sonia Fox

Lousie Hopkins

Jessica Okosun

Sally F. Barrington

Ingo Ringshausen

Alan G. Ramsay

Maria Calaminici

Kim Linton

Mark Bishton

机构：

[1] University of Birmingham,Cancer Research UK Clinical Trials Unit (CRCTU)

[2] National Cancer Research Institute,Division of Cancer Sciences

[3] University of Manchester,Barts Cancer Institute

[4] Queen Mary University of London,King’s College London and Guy’s and St Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences

[5] King’s College London,UCL Cancer Institute

[6] King’s Health Partners,School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine

[7] University College London,Department of Cellular Pathology Barts Health and Centre for Haemato

[8] King’s College London,Oncology, Barts Cancer Institute

[9] Queen Mary University of London,Department of Medical Oncology

[10] The Christie NHS Foundation Trust,Translational Medical Sciences

[11] University of Nottingham,Department of Haematology

[12] Nottingham University Hospitals NHS Trust,undefined

来源：

BMC Cancer | / 24卷

关键词：

Clinical trial; Relapsed follicular lymphoma; Bayesian power prior methodology; Adaptive design; Epcoritamab; Lenalidomide;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 137 条

[1]

Marcus R(2017)Obinutuzumab for the First-Line Treatment of Follicular Lymphoma N Engl J Med 377 1331-44

[2]

Davies A(2015)Early Relapse of Follicular Lymphoma after Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study J Clin Oncol 33 2516-22

[3]

Ando K(2016)Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up Ann Oncol 27 v83-90

[4]

Klapper W(2016)Obinutuzumab plus Bendamustine followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine alone in patients with Rituximab-Refractory Indolent Non-hodgkin Lymphoma: updated results of the GADOLIN Study Blood 128 615-8

[5]

Opat S(2010)Rituximab maintenance treatment of relapsed/resistant follicular non-hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study J Clin Oncol 28 2853-66

[6]

Owen C(2018)Overall Survival Benefit in patients with Rituximab-Refractory Indolent Non-hodgkin Lymphoma who received Obinutuzumab Plus Bendamustine induction and Obinutuzumab Maintenance in the GADOLIN Study J Clin Oncol 36 2259-69

[7]

Casulo C(2020)DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing EBioMedicine 52 102625-68

[8]

Byrtek M(2021)Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment Blood Cancer J 11 38-200

[9]

Dawson KL(2021)Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-hodgkin lymphoma: an open-label, phase 1/2 study Lancet 398 1157-42

[10]

Zhou X(2023)Epcoritamab SC Monotherapy Leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: First Data Disclosure from the Epcore NHL-1 follicular lymphoma dose-expansion cohort Blood 142 1655-81

← 1 2 3 4 5 6 7 8 9 10 →